Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Janumet (sitagliptin and metformin HCl) by Year
Janumet (sitagliptin and metformin HCl) — Worldwide sales ($M) ($M)
Merck Janumet (sitagliptin and metformin HCl): $940M in FY2025, up 0.5% from a year earlier.
Where the FY2025 figure comes from
“|| Janumet | 207 | 171 | 378 | 247 | 251 | 498 | 243 | 199 | 940 | -32 | -33 | -24 | -25”
Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Janumet (sitagliptin and metformin HCl) — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 940 | +0.5% | Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗ |
| FY2024 | Dec 31, 2024 | 935 | -20.6% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 1,177 | -30.8% | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 1,700 | -13.4% | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2021 | Dec 31, 2021 | 1,964 | -0.4% | Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗ |
| FY2020 | Dec 31, 2020 | 1,971 | -3.4% | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
| FY2019 | Dec 31, 2019 | 2,041 | -8.4% | Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗ |
| FY2018 | Dec 31, 2018 | 2,228 | +3.2% | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2017 | Dec 31, 2017 | 2,158 | -2.0% | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| FY2016 | Dec 31, 2016 | 2,201 | – | Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗ |
Breakdown
What makes up janumet (sitagliptin and metformin HCl)
- Janumet (sitagliptin and metformin HCl) — U.S. sales ($M)268 · FY2025
- Janumet (sitagliptin and metformin HCl) — International sales ($M)672 · FY2025
- Janumet (sitagliptin and metformin HCl) — Worldwide reported growth YoY (%)1.0% · FY2025
- Janumet (sitagliptin and metformin HCl) — Worldwide constant-currency (ex-exchange) growth YoY (%)2.0% · FY2025
Cite this data
StockData. (2026). Merck Janumet (sitagliptin and metformin HCl) ($M), annual FY2016–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-janumet
See every metric in the Merck KPI table. Data updated Oct 26, 2026.